AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 181 min read$CERS

Jensen Chrystal sold $90K of CERS

Jensen Chrystal (Chief Legal Officer) sold 30,000 shares of CERUS CORP (CERS) at $2.98 on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jensen Chrystal
Published Aug 18, 2026, 12:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
high confidence
Mentioned
$CERS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The disclosed transaction is an open-market sale of 30,000 shares at $2.9843, totaling $89,529, with holdings after the sale of 936,657 shares, and it states the sale was under a pre-arranged 10b5-1 plan.

02

Market read

Insider selling headlines may draw short-term attention, but the 10b5-1 structure and lack of new company fundamentals make it low-conviction for trading decisions.

03

What to watch

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than a view on Cerus fundamentals; the article provides no context on total planned sales or remaining tranche size.

Relevance 2/10Novelty 3/10Timing: filed/posted on 2026-08-17 after-hours

Background

The article is a SEC Form 4 insider transaction disclosure for Cerus Corp, reported by its Chief Legal Officer.

Company-level read

Ticker impact

$CERSNeutralHigh confidence
Context

Cerus Corp disclosed a Form 4 showing Chief Legal Officer Jensen Chrystal sold 30,000 shares at $2.9843 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely minimal impact on the stock, unless traders extrapolate unusual selling beyond the plan.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational, financial, or regulatory information.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Traders may treat the sale as a sentiment signal if they believe the 10b5-1 plan timing coincides with a near-term catalyst or valuation concern.

Key entities

  • issuer
    CERUS CORP

    Company whose insider transaction was disclosed on Form 4.

  • insider
    Jensen Chrystal

    Chief Legal Officer reporting the sale.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan intended to reduce timing-based inference from insider trades.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CERS insider trading history →

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min